Move to topTop
September 28, 2017

TOKYO, JAPAN - September 28, 2017 - Terumo Corporation (TSE: 4543) announced today that its new Innovation Center of its neurovascular and endovascular intervention businesses has opened on September 25th in California, United States.

The facility consolidates Terumo's Neurovascular Division's finance and administrative functions, global marketing and sales activities, research and development center and manufacturing, including a state-of-the-art neuroradiology imaging lab. The area of the complex is nearly doubled and is expected to support its business growth in the rapidly growing neurovascular market.

The Neurovascular Division has been developing some endovascular products for Terumo Interventional Systems Division by leveraging its resources and technologies. The opening of the new Innovation Center accelerates development of therapeutic devices with the aim of launching the products globally.

As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world through providing "Total Quality": high quality in all aspect of product, supply and service.

About the Innovation Center

Location Aliso Viejo, California, United States
Business Development, manufacture, and sale of neurovascular/endovascular intervention
Products Embolization coils, stents for neurovascular, balloon catheters, embolization beads, and many other related products
Opening September, 2017
Site area 205,000 square feet
Employees More than 800

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.